EUR 24 Million Biotechnolgy Invest Rentschler Invests in Stainless Steel Bioreactor Manufacturing
Rentschler Biotechnologie announces the investment of €24m to build a Twin system with two 3,000 L stainless steel bioreactors mainly targeting market supply at the company’s site in Laupheim, Germany. The Twin system should be operational in early 2017.
Laupheim/Germany – The new Twin system is designed for running two main bioreactors in parallel with one shared downstream processing unit thus providing higher throughput while reducing incremental labor costs involved. It integrates well into the existing 3,000 L GMP line and will more than double the production capacities for cell culture-derived proteins. The Twin system allows the company to run cell culture processes in fed-batch mode with a very high output in a single suite.
In the last few years, Rentschler has been heavily investing in single-use technology and only recently announced that it will add a new 2,000 L single-use bioreactor. Nevertheless, manufacturing in stainless steel is far from being outdated. The company is experiencing a high demand for stainless steel bioreactor capacity, mainly for market supply, but also for late clinical phases. The criteria for bioreactor selection includes the characteristics of the product to be manufactured, the approval phase, the expected volume requirements, the required flexibility, and competitive pricing due to optimal technological fit.